Cancer Therapies

Amgen Shares Dip On Light 2021 Outlook, Paused Studies

HC Wainwright: G1 Therapeutics Is Targeting 'Potential Blockbuster' Oncology Markets

Incyte Falls 20% After Cancer Drug Fails Phase 3 Trial

HC Wainwright: G1 Therapeutics Is Targeting 'Potential Blockbuster' Oncology Markets

Incyte Falls 20% After Cancer Drug Fails Phase 3 Trial

Janney Says Bluebird's Therapies Are 'Encouraging,' But Stock Is Fairly Valued

Checkpoint Therapeutics Wins A New Bull As Company's 'Plan Is Quickly Coming Together'

Janney Says Bluebird's Therapies Are 'Encouraging,' But Stock Is Fairly Valued

Checkpoint Therapeutics Wins A New Bull As Company's 'Plan Is Quickly Coming Together'

Gilead's Yescarta Cancer Treatment Approved, Some Analysts Shrug

Puma Biotech Makes Big Breakthrough In Breast Cancer Treatment